Hepatitis B new drug "Kule" listed

on December 6,, Guangdong Jinghao Pharmaceutical Technology Development Co., Ltdheld a press conference on the listing of a new class of drugs developed by the company and produced by Zhejiang Fuwei Pharmaceutical Co., Ltdat the Baiyun International Conference Center in GuangzhouIt is understood that this year is the 40th anniversary of the discovery of hepatitis B virusChronic hepatitis B virus is one of the four major infectious diseases that seriously affect thehealthof our people, and the treatment of anti-hepatitis B virus is the key to the treatment of slow hepatitis B"Jule" is the first batch ofdrugproduction order after the rectification of the state to obtain a new class of new drug certificate and allow the production of products, but also China's treatment of hepatitis B anti-virusdrugsthe market with independent intellectual property rights of patented products, its clinical research has been the Ministry of Science and Technology Technology Small and Medium Enterprises Technology Innovation Fund and Guangzhou City Science and Technology Research Program project fundingExperts said that the introduction of the product, is expected to break the long-term monopoly of foreign pharmaceutical companies in China's hepatitis B antiviral drug market situationGuangdong Jinghao Pharmaceutical Technology Development Co., Ltdis adrug research, development, production, promotion and sales of private science and technology enterprises The company started its own business to research and development of antiviral drugs as the core, especially hepatitis B (HBV), HIV (HIV) two major infectious diseases of high-tech products development and research In the successful development of independent intellectual property rights of hepatitis B anti-poison class II new drugs can be glycoside monophosphate adenosine and a new class of drugs "Jule" on the basis of the company will further increase investment in research and development, adhere to the anti-viral new drug "successful one, in the research two, three projects" research and development ideas, and strive to create greater achievements in the field of antiviral drugs At present, Jinghao Pharmaceutical Company has four subsidiaries of Jinghao New Drug Research and Development Center, Rao Pingfuwei Pharmaceuticals, Zhejiang Fuwei Pharmaceutical Co., Ltd and Guangdong Fuwei Pharmaceutical Co., Ltd (Reporter Xu Shuiyuan)